MARCADORES PRONOSTICOS DE SOBREVIDA EN PACIENTES CON CANCER DE ENDOMETRIO EN EL NORTE DE NORUEGA
Columnista Experta de SIIC A Ørbo
en colaboración con
Primera edición en siicsalud:
23 de junio, 2004
Sección Artículos originales,
subsección
Expertos de Iberoamérica,
página
/des/expertocompleto.php/66655
Especialidad principal:
Oncología
Especialidades relacionadas:
Anatomía Patológica,Epidemiología,Obstetricia y Ginecología,
A.B. Vereide, M. Arnes, B. Straume, J.M. Maltau, A. Ørbo. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasi. A pilot study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone., Gynecological Oncology 91:526-533
Anne Ørbo, M.N. Nilsen, M.S. Arnes, I. Pettersen, K. Larsen.Expresseion of MLH1, MSH2, MSH6 and PTEN related to cancer development or coexistent cancer in 68 patients with endometrial hyperplasia and known follow-up, International Journal of Gynecological Pathology 22:141-148
Anne Ørbo, M. Rydningen, B. Straume, S. Lysne Significance of morphometric DNA cytometric features anfd other prognostic markers on survival of endometrial cancer patients in Northern Norway., International JournaL OF Gynecological Cancer 12:49-56
Anne Ørbo, K. Eklo, M. Kopp, B. Straume.A semiautomated test for microsattelite instability and its significance for prognosis of sporadic endometrial cancer in Northern Norway, Journal of Gynecological Pathology 21:27-33
Jan P.A.Baak, A. Ørbo, M.A.M. Broeckaert, P.J. Diest, et al. Prospective nulticenter long-term evaluation of the computerized morphometric D-score to predict the outcome of endometrial hyperplasias., American Journal of Surgery Pathology 25:930-935
Anne Ørbo, P.A.Baak, I. Kleivan, S. Lysne, P.S. Prytz, M.A.M. Broeckaert, A. Slappendel, H. J. Tichelaar Computerized morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long term retrospective study from Northern Norway., Journal of Clinical Pathology 53:697-703
A Ørbo
